Skip to main content

Articles

Page 3 of 33

  1. Health-related quality of life (HR-QoL) is an important outcome for patients and crucial for demonstrating the value of new treatments. Health utility estimates in subjective cognitive decline (SCD) and mild c...

    Authors: Sandar Aye, Vincent Bouteloup, Ashley Tate, Anders Wimo, Ron Handels, Delphine Jean, Bengt Winblad and Linus Jönsson
    Citation: Alzheimer's Research & Therapy 2023 15:200
  2. Understanding the pathological characteristics of various mild cognitive impairment (MCI) subtypes is crucial for the differential diagnosis of dementia. The purpose of this study was to feature divergent symp...

    Authors: Chao Du, Mingxi Dang, Kewei Chen, Yaojing Chen and Zhanjun Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:199
  3. Subjective cognitive complaints (SCC) have been mostly studied in the context of Alzheimer’s disease in memory clinic settings. The potential of combining SCC with genetic information and blood biomarkers of ...

    Authors: Laura Perna, Hannah Stocker, Lena Burow, Léon Beyer, Kira Trares, Carolin Kurz, Selim Gürsel, Bernd Holleczek, Maia Tatò, Konrad Beyreuther, Ute Mons, Klaus Gerwert, Robert Perneczky, Ben Schöttker and Hermann Brenner
    Citation: Alzheimer's Research & Therapy 2023 15:198
  4. Cholesterol plays important roles in β-amyloid (Aβ) metabolism and atherosclerosis. However, the relationships of plasma cholesterol levels with Aβ and cerebral small vessel disease (CSVD) burdens are not full...

    Authors: Sung Hoon Kang, Heejin Yoo, Bo Kyoung Cheon, Yu Hyun Park, Soo-Jong Kim, Hongki Ham, Hyemin Jang, Hee Jin Kim, Kyungmi Oh, Seong-Beom Koh, Duk L. Na, Jun Pyo Kim and Sang Won Seo
    Citation: Alzheimer's Research & Therapy 2023 15:197
  5. Genomic study of cognition decline while considering baseline cognition and lifestyle behaviors is scarce. We aimed to evaluate the impact of a polygenic score for general cognition on cognition decline rate, ...

    Authors: Tingting Liu, Changwei Li, Ruiyuan Zhang, Eugenia Flores Millender, Hongyu Miao, Michael Ormsbee, Jinzhen Guo, Adrianna Westbrook, Yang Pan, Jing Wang and Tanika N. Kelly
    Citation: Alzheimer's Research & Therapy 2023 15:196
  6. The Alzheimer’s disease (AD) risk gene ABCA7 has suggested functions in lipid metabolism and the immune system. Rare premature termination codon (PTC) mutations and an expansion of a variable number of tandem rep...

    Authors: Lena Duchateau, Fahri Küҫükali, Arne De Roeck, Mandy M. J. Wittens, Joke Temmerman, Ilse Weets, Maarten Timmers, Sebastiaan Engelborghs, Maria Bjerke and Kristel Sleegers
    Citation: Alzheimer's Research & Therapy 2023 15:195
  7. Inflammation plays a key role in the development of dementia, but its link to early biomarkers, particularly those in plasma or neuroimaging, remains elusive. This study aimed to investigate the association be...

    Authors: Amber Yaqub, Samer R. Khan, Meike W. Vernooij, P. Martin van Hagen, Robin P. Peeters, M. Arfan Ikram, Layal Chaker and Virgil A. S. H. Dalm
    Citation: Alzheimer's Research & Therapy 2023 15:194
  8. The pathological process of Alzheimer’s disease (AD) typically takes decades from onset to clinical symptoms. Early brain changes in AD include MRI-measurable features such as altered functional connectivity (...

    Authors: Yujian Diao, Bernard Lanz and Ileana Ozana Jelescu
    Citation: Alzheimer's Research & Therapy 2023 15:193
  9. We have proposed that cognitive resilience (CR) counteracts brain damage from Alzheimer’s disease (AD) or AD-related dementias such that older individuals who harbor neurodegenerative disease burden sufficient...

    Authors: Thanaphong Phongpreecha, Dana Godrich, Eloise Berson, Camilo Espinosa, Yeasul Kim, Brenna Cholerton, Alan L. Chang, Samson Mataraso, Syed A. Bukhari, Amalia Perna, Koya Yakabi, Kathleen S. Montine, Kathleen L. Poston, Elizabeth Mormino, Lon White, Gary Beecham…
    Citation: Alzheimer's Research & Therapy 2023 15:192
  10. Alzheimer’s disease is a prevalent disease with a heavy global burden. Proteomics is the systematic study of proteins and peptides to provide comprehensive descriptions. Aiming to obtain a more accurate and co...

    Authors: Yuye Wang, Yu Sun, Yu Wang, Shuhong Jia, Yanan Qiao, Zhi Zhou, Wen Shao, Xiangfei Zhang, Jing Guo, Bin Zhang, Xiaoqian Niu, Yi Wang and Dantao Peng
    Citation: Alzheimer's Research & Therapy 2023 15:191
  11. There is a tremendous need for identifying reliable blood-based biomarkers for Alzheimer’s disease (AD) that are tied to the biological ATN (amyloid, tau and neurodegeneration) framework as well as clinical as...

    Authors: Zhengshi Yang, Karthik Sreenivasan, Erin N. Toledano Strom, Amanda M. Leisgang Osse, Lorenzo Gabriel Pasia, Celica Glenn Cosme, Maya Rae N. Mugosa, Emma Léa Chevalier, Aaron Ritter, Justin B. Miller, Dietmar Cordes, Jeffrey L. Cummings and Jefferson W. Kinney
    Citation: Alzheimer's Research & Therapy 2023 15:190
  12. The mismatch between the limited availability versus the high demand of participants who are in the pre-dementia phase of Alzheimer’s disease (AD) is a bottleneck for clinical studies in AD. Nevertheless, pote...

    Authors: Ilse Bader, Ilona Bader, Isadora Lopes Alves, David Vállez García, Bruno Vellas, Bruno Dubois, Mercè Boada, Marta Marquié, Daniele Altomare, Philip Scheltens, Rik Vandenberghe, Bernard Hanseeuw, Michael Schöll, Giovanni B. Frisoni, Frank Jessen, Agneta Nordberg…
    Citation: Alzheimer's Research & Therapy 2023 15:189
  13. The over-activation of adenosine A2A receptors (A2AR) is closely implicated in cognitive impairments of Alzheimer's disease (AD). Growing evidence shows that A2AR blockade possesses neuroprotective effects on AD....

    Authors: Qi Ji, Yang Yang, Yun Xiong, Ying-Jie Zhang, Jun Jiang, Li-Ping Zhou, Xiao-Hui Du, Chun-Xiang Wang and Zhi-Ru Zhu
    Citation: Alzheimer's Research & Therapy 2023 15:187
  14. Synapse loss is an early event that precedes neuronal death and symptom onset and is considered the best neuropathological correlate of cognitive decline in Alzheimer’s disease (AD). Vesicle-associated membran...

    Authors: Julie Goossens, Alba Cervantes González, Nele Dewit, Laia Lidón, Juan Fortea, Daniel Alcolea, Alberto Lleó, Olivia Belbin and Eugeen Vanmechelen
    Citation: Alzheimer's Research & Therapy 2023 15:186
  15. Alzheimer's disease (AD) is a neurodegenerative disease and the main cause for dementia. The irreversible neurodegeneration leads to a gradual loss of brain function characterized predominantly by memory loss....

    Authors: Xiaozhu Liu, Samuel Halvorsen, Nathan Blanke, Margaret Downs, Thor D. Stein, Irving J. Bigio, Joseph Zaia and Yanhang Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:185
  16. In MAPT (Multidomain Alzheimer Preventive Trial), a cognitive effect of multidomain intervention (MI) was showed in non-demented subjects with positive amyloid PET. However, screening eligible patients for mul...

    Authors: Julien Delrieu, Bruno Vellas, Sophie Guyonnet, Christelle Cantet, Vitaliy Ovod, Yan Li, James Bollinger, Randall Bateman and Sandrine Andrieu
    Citation: Alzheimer's Research & Therapy 2023 15:183
  17. To enable successful inclusion of electroencephalography (EEG) outcome measures in Alzheimer’s disease (AD) clinical trials, we retrospectively mapped the progression of resting-state EEG measures over time in...

    Authors: Elliz P. Scheijbeler, Willem de Haan, Cornelis J. Stam, Jos W. R. Twisk and Alida A. Gouw
    Citation: Alzheimer's Research & Therapy 2023 15:182
  18. APOE genotype is the greatest genetic risk factor for sporadic Alzheimer’s disease (AD). APOE4 increases AD risk up to 12-fold compared to APOE3, an effect that is greater in females. Evidence suggests that one-w...

    Authors: Deebika Balu, Ana C. Valencia-Olvera, Austin Nguyen, Mehul Patnam, Jason York, Francesco Peri, Frank Neumann, Mary Jo LaDu and Leon M. Tai
    Citation: Alzheimer's Research & Therapy 2023 15:181
  19. Alzheimer’s disease involves accumulating amyloid (A) and tau (T) pathology, and progressive neurodegeneration (N), leading to the development of the AD clinical syndrome. While several markers of N have been ...

    Authors: Rigina L. Gallagher, Rebecca Langhough Koscik, Jason F. Moody, Nicholas M. Vogt, Nagesh Adluru, Steven R. Kecskemeti, Carol A. Van Hulle, Nathaniel A. Chin, Sanjay Asthana, Gwendlyn Kollmorgen, Ivonne Suridjan, Cynthia M. Carlsson, Sterling C. Johnson, Douglas C. Dean III, Henrik Zetterberg, Kaj Blennow…
    Citation: Alzheimer's Research & Therapy 2023 15:180
  20. Current treatments for Alzheimer’s disease (AD) have largely failed to yield significant therapeutic benefits. Novel approaches are desperately needed to help address this immense public health issue. Data sug...

    Authors: Nancy R. Stallings, Melissa A. O’Neal, Jie Hu, Zhong-Jian Shen and James S. Malter
    Citation: Alzheimer's Research & Therapy 2023 15:179
  21. The effect of amyloid-β (Aβ) on cognitive impairment in patients with small subcortical infarction remains controversial, although a growing body of evidence shows a substantial overlap between Alzheimer’s dis...

    Authors: Sung Hoon Kang, Minwoong Kang, Jung Hoon Han, Eun Seong Lee, Keon-Joo Lee, Su Jin Chung, Sang-Il Suh, Seong-Beom Koh, Jae Seon Eo, Chi Kyung Kim and Kyungmi Oh
    Citation: Alzheimer's Research & Therapy 2023 15:178
  22. Authors: Patricia Diaz‑Galvan, Giulia Lorenzon, Rosaleena Mohanty, Gustav Mårtensson, Enrica Cavedo, Simone Lista, Andrea Vergallo, Kejal Kantarci, Harald Hampel, Bruno Dubois, Michel J. Grothe, Daniel Ferreira and Eric Westman
    Citation: Alzheimer's Research & Therapy 2023 15:177

    The original article was published in Alzheimer's Research & Therapy 2023 15:117

  23. Mild cognitive impairment (MCI) is often considered an early stage of dementia, with estimated rates of progression to dementia up to 80–90% after approximately 6 years from the initial diagnosis. Diagnosis of...

    Authors: Kevin Blanco, Stefanny Salcidua, Paulina Orellana, Tania Sauma-Pérez, Tomás León, Lorena Cecilia López Steinmetz, Agustín Ibañez, Claudia Duran-Aniotz and Rolando de la Cruz
    Citation: Alzheimer's Research & Therapy 2023 15:176
  24. Development of in vivo biomarkers has shifted the diagnosis of Alzheimer’s disease (AD) from the later dementia stages of disease towards the earlier stages and has introduced the potential for pre-symptomatic...

    Authors: Bruno Dubois, Christine A. F. von Arnim, Nerida Burnie, Sasha Bozeat and Jeffrey Cummings
    Citation: Alzheimer's Research & Therapy 2023 15:175
  25. Soluble amyloid-beta oligomers (Aβo) begin to accumulate in the human brain one to two decades before a clinical diagnosis of Alzheimer’s disease (AD). The literature supports that soluble Aβo are implicated i...

    Authors: Audrey Hector, Chloé Provost, Benoît Delignat-Lavaud, Khadija Bouamira, Chahinez-Anissa Menaouar, Valérie Mongrain and Jonathan Brouillette
    Citation: Alzheimer's Research & Therapy 2023 15:174
  26. It is unknown if fluid biomarkers reflective of brain pathologies are useful in detecting and following a neurodegenerative process in individuals exposed to repetitive head impacts. This study explores the re...

    Authors: Charles Bernick, Guogen Shan, Aaron Ritter, Nicholas J. Ashton, Kaj Blennow, Juan Lantero-Rodriguez, Anniina Snellman and Henrik Zetterberg
    Citation: Alzheimer's Research & Therapy 2023 15:173
  27. Compared to standard neuro-diagnostic techniques, retinal biomarkers provide a probable low-cost and non-invasive alternative for early Alzheimer’s disease (AD) risk screening. We have previously quantified th...

    Authors: Edmund Arthur, Swetha Ravichandran, Peter J. Snyder, Jessica Alber, Jennifer Strenger, Ava K. Bittner, Rima Khankan, Stephanie L. Adams, Nicole M. Putnam, Karin R. Lypka, Juan A. Piantino and Stuart Sinoff
    Citation: Alzheimer's Research & Therapy 2023 15:172
  28. Alterations in mitochondrial DNA (mtDNA) levels have been observed in Alzheimer’s disease and are an area of research that shows promise as a useful biomarker. It is well known that not only are the mitochondr...

    Authors: Isabelle K. Gorham, Robert C. Barber, Harlan P. Jones and Nicole R. Phillips
    Citation: Alzheimer's Research & Therapy 2023 15:171
  29. The glymphatic system is a crucial component in preserving brain homeostasis by facilitating waste clearance from the central nervous system (CNS). Aquaporin-4 (AQP4) water channels facilitate the continuous i...

    Authors: Pablo Mohaupt, Jérôme Vialaret, Christophe Hirtz and Sylvain Lehmann
    Citation: Alzheimer's Research & Therapy 2023 15:170
  30. The first predominant clinical symptoms of dementia with Lewy bodies (DLB) are highly variable; however, the prognosis based on initial predominant symptoms remains poorly understood.

    Authors: Clément Aveneau, David Wallon, Bertrand Degos, Alexandre Obadia, Claire Hourregue, Sarah Benisty, Béatrice Garcin, Julien Dumurgier and Claire Paquet
    Citation: Alzheimer's Research & Therapy 2023 15:169
  31. Tauopathies are a group of neurodegenerative disorders characterized by the aggregation of the microtubule-associated protein tau. Aggregates of misfolded tau protein are believed to be implicated in neuronal ...

    Authors: Jeffrey L. Cummings, M. Isabel Gonzalez, Martyn C. Pritchard, Patrick C. May, Leticia M. Toledo-Sherman and Glenn A. Harris
    Citation: Alzheimer's Research & Therapy 2023 15:168
  32. Prevalence of overall cognitive impairment based on each participant’s performance across a neuropsychological battery is challenging; consequently, we define and validate a dichotomous cognitive impairment/no...

    Authors: Megan E. O’Connell, Helena Kadlec, Lauren E. Griffith, Christina Wolfson, Geva Maimon, Vanessa Taler, Susan Kirkland and Parminder Raina
    Citation: Alzheimer's Research & Therapy 2023 15:167
  33. Exposure to repetitive head impacts (RHI) in American football players can lead to cognitive impairment and dementia due to neurodegenerative disease, particularly chronic traumatic encephalopathy (CTE). The p...

    Authors: Robert A. Stern, Diana Trujillo-Rodriguez, Yorghos Tripodis, Surya V. Pulukuri, Michael L. Alosco, Charles H. Adler, Laura J. Balcer, Charles Bernick, Zachary Baucom, Kenneth L. Marek, Michael D. McClean, Keith A. Johnson, Ann C. McKee, Thor D. Stein, Jesse Mez, Joseph N. Palmisano…
    Citation: Alzheimer's Research & Therapy 2023 15:166
  34. There has been increasing interest in cortical microstructure as a complementary and earlier measure of neurodegeneration than macrostructural atrophy, but few papers have related cortical diffusion imaging to...

    Authors: Mario Torso, Gerard R. Ridgway, Michele Valotti, Ian Hardingham and Steven A. Chance
    Citation: Alzheimer's Research & Therapy 2023 15:165
  35. Hyperhomocysteinemia (HHcy) has been linked to development of Alzheimer’s disease (AD) neuropathologically characterized by the accumulation of amyloid β (Aβ). Microglia (MG) play a crucial role in uptake of A...

    Authors: Xianwei Wang, Lu Liu, Xiaohua Jiang, Jason Saredy, Hang Xi, Ramon Cueto, Danni Sigler, Mohsin Khan, Sheng Wu, Yong Ji, Nathaniel W. Snyder, Wenhui Hu, Xiaofeng Yang and Hong Wang
    Citation: Alzheimer's Research & Therapy 2023 15:164
  36. The arrival of new disease-modifying treatments for Alzheimer’s disease (AD) requires the identification of subjects at risk in a simple, inexpensive, and non-invasive way. With tools allowing an adequate scre...

    Authors: Francisco Martínez-Dubarbie, Armando Guerra-Ruiz, Sara López-García, Carmen Lage, Marta Fernández-Matarrubia, Jon Infante, Ana Pozueta-Cantudo, María García-Martínez, Andrea Corrales-Pardo, María Bravo, Marcos López-Hoyos, Juan Irure-Ventura, Pascual Sánchez-Juan, María Teresa García-Unzueta and Eloy Rodríguez-Rodríguez
    Citation: Alzheimer's Research & Therapy 2023 15:163
  37. Chronic stress and depression are potential risk factors for mild cognitive impairment and dementia, including Alzheimer disease. The aim was to investigate whether any such risk is additive.

    Authors: Johanna Wallensten, Gunnar Ljunggren, Anna Nager, Caroline Wachtler, Nenad Bogdanovic, Predrag Petrovic and Axel C. Carlsson
    Citation: Alzheimer's Research & Therapy 2023 15:161
  38. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13195-021-00769-9.

    Authors: Panchanan Maiti, Zackary Bowers, Ali Bourcier-Schultz, Jarod Morse and Gary L. Dunbar
    Citation: Alzheimer's Research & Therapy 2023 15:162
  39. Authors: Andreas Giannisis, Asma Al-Grety, Henrik Carlsson, Jennifer C. Howell, William T. Hu, Kim Kultima and Henrietta M. Nielsen
    Citation: Alzheimer's Research & Therapy 2023 15:160

    The original article was published in Alzheimer's Research & Therapy 2023 15:119

  40. Although increasing physical activity (PA) has been suggested to prevent and manage cognitive decline and dementia, its economic impact on healthcare systems and society is largely unknown. This study aimed to...

    Authors: Weixin Li, Kun-Woo Rafael Kim, Donglan Zhang, Bian Liu, Christine M. Dengler-Crish, Ming Wen, Lu Shi, Xi Pan, Yian Gu and Yan Li
    Citation: Alzheimer's Research & Therapy 2023 15:159
  41. People with mild cognitive impairment (MCI) experience a loss of cognitive functions, whose mechanism is characterized by aberrant structure‒function (SC-FC) coupling and topological attributes of multiple net...

    Authors: Jingsong Wu, Youze He, Shengxiang Liang, Zhizhen Liu, Jia Huang, Weilin Liu, Jing Tao, Lidian Chen, Chetwyn C. H. Chan and Tatia M. C. Lee
    Citation: Alzheimer's Research & Therapy 2023 15:158
  42. Plasma phosphorylated tau (p-tau) has emerged as a promising biomarker for Alzheimer’s disease (AD). Studies have reported strong associations between p-tau and tau-PET that are mainly driven by differences be...

    Authors: Nidhi S. Mundada, Julio C. Rojas, Lawren Vandevrede, Elisabeth H. Thijssen, Leonardo Iaccarino, Obiora C. Okoye, Ranjani Shankar, David N. Soleimani-Meigooni, Argentina L. Lago, Bruce L. Miller, Charlotte E. Teunissen, Hillary Heuer, Howie J. Rosen, Jeffrey L. Dage, William J. Jagust, Gil D. Rabinovici…
    Citation: Alzheimer's Research & Therapy 2023 15:157
  43. Neuron-derived extracellular vesicles (NDEVs) in blood may be used to derive biomarkers for the effects of exercise in Alzheimer’s disease (AD). For this purpose, we studied changes in neuroprotective proteins...

    Authors: Francheska Delgado-Peraza, Carlos Nogueras-Ortiz, Anja Hviid Simonsen, De’Larrian DeAnté Knight, Pamela J. Yao, Edward J. Goetzl, Camilla Steen Jensen, Peter Høgh, Hanne Gottrup, Karsten Vestergaard, Steen Gregers Hasselbalch and Dimitrios Kapogiannis
    Citation: Alzheimer's Research & Therapy 2023 15:156

    The Correction to this article has been published in Alzheimer's Research & Therapy 2024 16:18

  44. Gamma (γ) brain oscillations are dysregulated in Alzheimer’s disease (AD) and can be modulated using transcranial alternating stimulation (tACS). In the present paper, we describe the rationale and design of a...

    Authors: Daniele Altomare, Alberto Benussi, Valentina Cantoni, Enrico Premi, Jasmine Rivolta, Chiara Cupidi, Alessandro Martorana, Emiliano Santarnecchi, Alessandro Padovani, Giacomo Koch and Barbara Borroni
    Citation: Alzheimer's Research & Therapy 2023 15:155
  45. Preclinical studies highlight the importance of endogenous cannabinoids (endocannabinoids; eCBs) in neurodegeneration. Yet, prior observational studies focused on limited outcome measures and assessed only few...

    Authors: Shiraz Vered, Alexa S. Beiser, Liron Sulimani, Sharon Sznitman, Mitzi M. Gonzales, Hugo J. Aparicio, Charles DeCarli, Matthew R. Scott, Saptaparni Ghosh, Gil M. Lewitus, David Meiri, Sudha Seshadri and Galit Weinstein
    Citation: Alzheimer's Research & Therapy 2023 15:154
  46. Depression and dementia are both common diseases. Although new cases of depression are more common in younger adults, there is a second peak at the age of 50 years suggesting a different pathological process. ...

    Authors: Lindsey I. Sinclair, Asher Mohr, Mizuki Morisaki, Martin Edmondson, Selina Chan, A. Bone-Connaughton, Gustavo Turecki and Seth Love
    Citation: Alzheimer's Research & Therapy 2023 15:153

    The Correction to this article has been published in Alzheimer's Research & Therapy 2024 16:33

  47. The relationship of glucosamine use with incident dementia in the older population remains uncertain. We aimed to evaluate the longitudinal association between habitual glucosamine supplement and the risk of c...

    Authors: Chun Zhou, Yanjun Zhang, Sisi Yang, Ziliang Ye, Qimeng Wu, Mengyi Liu, Panpan He, Yuanyuan Zhang and Xianhui Qin
    Citation: Alzheimer's Research & Therapy 2023 15:152
  48. Rapid-eye movement (REM) sleep highly depends on the activity of cholinergic basal forebrain (BF) neurons and is reduced in Alzheimer’s disease. Here, we investigated the associations between the volume of BF ...

    Authors: Claire André, Marie-Ève Martineau-Dussault, Véronique Daneault, Hélène Blais, Sonia Frenette, Dominique Lorrain, Carol Hudon, Célyne Bastien, Dominique Petit, Alexandre Lafrenière, Cynthia Thompson, Jacques Montplaisir, Nadia Gosselin and Julie Carrier
    Citation: Alzheimer's Research & Therapy 2023 15:151